SCHEMBL29709355

SCHEMBL29709355

CC(C)(O)CC[C@H](C[C@H](O)[C@H](Cc1cccc(F)c1)NC(=O)c1cnc2ccccc2n1)C(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 20/20 1.00
CHRM2 P08172 1/20 1.00
CCR5 P51681 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL995030 1.00 CCR1 (1.00) CCR1CHRM2CCR5
SCHEMBL30059121 1.00 CCR1 (1.00) CCR1CHRM2CCR5
SCHEMBL993794 0.94 CCR1 (0.90) CCR1CHRM2CCR5
SCHEMBL18776064 0.93 CCR1 (0.87) CCR1CHRM2CCR5
SCHEMBL9910989 0.91 CCR1 (0.87) CCR1CHRM2CCR5
SCHEMBL993584 0.91 CCR1 (0.83) CCR1CHRM2CCR5
SCHEMBL6807717 0.90 CCR1 (0.82) CCR1CHRM2CCR5
SCHEMBL6251094 0.90 CCR1 (0.82) CCR1CHRM2CCR5
SCHEMBL6248473 0.90 CCR1 (0.82) CCR1CHRM2CCR5
SCHEMBL6249065 0.90 CCR1 (0.81) CCR1CHRM2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026848-A1 IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-01-23 US claimed
WO-2023023269-A1 IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-02-23 WO claimed
EP-4608403-A1 MODULATORS AND USES THEREOF Hadasit Medical Research Services&Development Ltd. (IL) 2025-09-03 EP disclosed
US-20250213647-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA 2025-07-03 US disclosed
US-20250026848-A1 IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-01-23 US disclosed
WO-2024089691-A1 MODULATORS AND USES THEREOF HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD (IL) 2024-05-02 WO disclosed
WO-2023192319-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA (US) 2023-10-05 WO disclosed
EP-4143235-A1 METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION IncellDx, Inc. (US) 2023-03-08 EP disclosed
WO-2023023269-A1 IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-02-23 WO disclosed
US-11364305-B2 Nanoparticle conjugates and uses thereof UNIVERSITY OF MIAMI (US) 2022-06-21 US disclosed